echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Keyue Pharmaceuticals will report the latest preclinical data of its lead project KP104 at the 18th European Conference on Complement and Human Disease

    Keyue Pharmaceuticals will report the latest preclinical data of its lead project KP104 at the 18th European Conference on Complement and Human Disease

    • Last Update: 2022-09-09
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Oral presentation at the congress on the favorable pharmacokinetic and pharmacodynamic properties of intravenous and subcutaneous administration of KP104 in relevant animal models, supporting further development as a potent inhibitor of complement replacement and terminal dual pathways

    Conference posters demonstrate synergistic effects of selective inhibition of the alternative and terminal pathways of complement in the treatment of complement-mediated diseases, including data from a new mouse model of C3 glomerulopathy (C3G)

    CAMBRIDGE, Mass.


    The conference will be held in Bern, Switzerland from 26 to 29 August


    The complement system is a complex protein pathway and an important part of innate immunity


    "Based on intellectual property licensed and developed by the University of Pennsylvania, Keyue's lead product, KP104, is designed to overcome the inherent pharmacokinetic and pharmacodynamic challenges of developing complement medicines


    Ke Yue Medicine has completed a Phase 1 first-in-human (FIH) study evaluating KP104, which achieved a clinical proof-of-mechanism (POM), and is initiating a Phase 2 clinical proof-of-concept (POC) trial across multiple indications


    Introduction to oral presentations

    Title: Pharmacokinetics/Pharmacodynamics of KP104, a Bifunctional Antibody Fusion Protein Complement Inhibitor, in C5/FCRN Humanized Transgenic Mice and Cynomolgus Monkeys

    Authors: Jay Ma1, Xiang Gao1, Takashi Miwa2, Damodar Gullipalli2, Sayaka Sato2, Wen-Chao Song2, Xihua Zhu3, Jianjun Zhang3, Chaomei He1, Helen Fu1, Richard Lee1, Frederick Beddingfield1,4, Wenru Song1, Ping Tsui*,1

    Abstract number: 126

    Session Topic: Scientific Session IV: Therapeutics

    Conference Date and Time: August 28, 2022 9:15-9:30 EST

    Executive Summary and Background: The results of this study demonstrate the optimal pharmacological characterization of KP104 in human C5 transgenic mice and non-human primates (NHPs), supporting its further development as a potent drug suitable for intravenous and subcutaneous administration.


    1 Keyue Medicine, Cambridge, MA, 2 Department of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, 3 Keyue Medicine, Suzhou, China, 4 Department of Dermatology, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, *corresponding author

    Introduction to posters

    Title: Design and Characterization of KP104: An Anti-C5 mAb and FH1-5 Bifunctional Fusion Protein Synergistically Inhibits Complement Alternative and Terminal Pathways

    Authors: Takashi Miwa1, Damodar Gullipalli1, Sayaka Sato1, Madhu Golla1, Xihua Zhu2, Jianjun Zhang2, Dongqiong Fei2, Ping Tsui3, Fengkui Zhang4, Wen-Chao Song1

    Poster No.


    Conference Topic: Poster Browsing Conference 2

    Conference Date and Time: August 28, 11:45-13:30 EST

    Poster abstract and background: The poster describes the design and preliminary characterization of KP104


    1 Department of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA, 2 Ke Yue Medicine, Suzhou, China, 3 Ke Yue Medicine, Cambridge, MA, USA, 4 Institute of Hematology, Chinese Academy of Medical Sciences, Tianjin, China

    Title: Therapeutic effect of anti-C5 mAb/FH1-5 bifunctional fusion protein in a mouse model of rapidly progressive lethal C3 nephropathy

    Authors: Sayaka Sato1, Takashi Miwa1, Damodar Gullipalli1, Lin Zhou1, Jianjun Zhang2, Xiaoxia Hu2, Bingbing Jiang2, Ping Tsui3, Wen-Chao Song1

    Poster No.


    Conference Topic: Poster Browsing Conference 2

    Conference Date and Time: August 28, 11:45-13:30 EST

    Abstract and background: C3 glomerulopathy (C3G) is a rare kidney disease caused by dysregulation of alternative pathway activity in the complement system for which there is currently no effective treatment


    1 Department of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA, 2 Keyue Medicine, Suzhou, China, 3 Keyue Medicine, Cambridge, Massachusetts, USA

    Statement: Dr.


    About KP104

    KP104 is the world's first bifunctional complement biopharmaceutical with a unique mechanism of action


    Source: Kira Pharmaceuticals

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.